Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s ...

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

Small cell lung cancer (SCLC), one of the deadliest types of lung cancer, is an aggressive tumor that metastasizes early compared to other cancers and can quickly develop resistance to chemotherapy — ...

MAIA Biotechnology enrolls first patient in expansion of phase 2 clinical trial for ateganosine in advanced non-small cell lung cancer: Chicago Friday, July 11, 2025, 12:00 Hrs [I ...

Researchers have now demonstrated for the first time that MNPs can trigger malignant changes in lung cells that are ...

AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...

Although the respiratory system is one of the main entry points for microplastics and nanoplastics (MNPs) from the air into ...